Characterization of isoniazid-resistant strains of Mycobacterium tuberculosis on the basis of phenotypic properties and mutations in katG

被引：36

作者：

Abate G. ^{[1
]}

Hoffner S.E. ^{[3
]}

Miörner H. ^{[2
]}

机构：

[1] Department of Mycobacteriology, Statens Serum Institut, Copenhagen

[2] Institute of Pathobiology, Medical Faculty, Addis Ababa University

[3] Microbiology and Tumorbiology Center, Karolinska Institute, Stockholm

来源：

European Journal of Clinical Microbiology and Infectious Diseases | 2001年 / 20卷 / 5期

关键词：

Codon; Tuberculosis; Catalase; Growth Pattern; Isoniazid;

D O I：

10.1007/PL00011272

中图分类号：

学科分类号：

摘要：

Forty isoniazid-resistant Mycobacterium tuberculosis isolates were characterized on the basis of phenotypic properties (i.e., catalase activity, MIC of isoniazid, and growth pattern in the presence of 7 different concentrations of isoniazid) and alterations in the katG gene (codons 315 and 463). Three different growth patterns could be distinguished: concentration-dependent inhibition of growth was observed in 29 strains, similar growth at all concentrations was seen in 7 strains, and enhanced growth at low concentrations of isoniazid was evident in 4 strains. The MIC of isoniazid was ≤4 μg/ml for 29 of 40 strains. Mutation at codon 315 of the katG was detected in 28 of 40 strains. However, only one of the seven strains for which the MIC of isoniazid was ≥16 μg/ml had mutation at this codon. Five of these seven strains for which the MIC was ≥16 μg/ml had no catalase activity. The results indicate that the MIC of isoniazid for a majority of strains is below the level achievable in serum. Therefore, isoniazid may be beneficial for the treatment of some cases of multidrug-resistant tuberculosis. Determination of catalase activity aids in the detection of isolates for which MICs are high and could, in conjunction with molecular methods, provide rapid detection of most isoniazid-resistant strains.

引用

页码：329 / 333

页数：4

共 32 条

[1] Global health situation and projections, (1992)
[2] The world health report. Life in the 21st century. A vision for all, (1998)
[3] Selwyn P.A., Hartel D., Lewis V.A., Schoenbaum E.E., Vermund S.H., Klein R.S., Walker A.T., Friedland G.H., A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection, New England Journal of Medicine, 320, pp. 545-550, (1989)
[4] Daley C.L., Small P.M., Schecter G.F., Schoolnik G.K., McAdam R.A., Jacobs W.R. Jr., Hopewell P.C., An outbreak of tuberculosis with accelerated progression among persons infected with the human immunodeficiency virus. An analysis using restriction fragment length polymorphism, New England Journal of Medicine, 326, pp. 231-235, (1992)
[5] Di Perri G., Cruciani M., Danzi M.C., Luzzati R., De-Checchi G., Malena M., Pizzighella S., Mazzi R., Solbiati M., Concia E., Bassetti D., Nosocomial epidemic of active tuberculosis among HIV-infected patients, Lancet, 2, pp. 1502-1504, (1989)
[6] Antituberculosis drug resistance in the world, (1997)
[7] Telenti A., Honore N., Bernasconi C., March J., Ortega A., Heym B., Takiff H.E., Cole S.T., Genotypic assessment of isoniazid and rifampicin resistance in Mycobacterium tuberculosis: A blind study at reference laboratory level, Journal of Clinical Microbiology, 35, pp. 719-723, (1997)
[8] Dessen A., Quemard A., Blanchard J.S., Jacobs W.R. Jr., Sacchettini J.C., Crystal structure and function of the isoniazid target of Mycobacterium tuberculosis, Science, 267, pp. 1638-1641, (1995)
[9] Mdluli K., Slayden R.A., Zhu Y., Ramaswamy S., Pan X., Mead D., Crane D.D., Musser J.M., Barry III C.E., Inhibition of Mycobacterium tuberculosis β-ketacyl ACP synthase by isoniazid, Science, 280, pp. 1607-1610, (1998)
[10] Dobner P., Rush-Gerdes S., Bretzel G., Feldmann K., Rifai M., Loscher T., Rinder H., Usefulness of Mycobacterium tuberculosis genomic mutations in the genes katG and inhA for the prediction of isoniazid resistance, International Journal of Tuberculosis and Lung Disease, 1, pp. 365-369, (1997)

← 1 2 3 4 →